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Abstract
The Receiver Operating Characteristic (ROC) surface is a generalization of ROC
curve and is widely used for assessment of the accuracy of diagnostic tests on three
categories. A complication called the verification bias, meaning that not all subjects
have their true disease status verified often occur in real application of ROC analysis.
This is a common problem since the gold standard test, which is used to generate
true disease status, can be invasive and expensive. In this paper, we will propose a
Bayesian approach for estimating the ROC surface based on continuous data under
a semi-parametric trinormality assumption. Our proposed method often adopted in
ROC analysis can also be extended to situation in the presence of verification bias. We
compute the posterior distribution of the parameters under trinormality assumption
by using a rank-based likelihood. Consistency of the posterior under mild conditions
is also established. We compare our method with the existing methods for estimating
ROC surface and conclude that our method performs well in terms of accuracy.
Key words: ROC surface; Verification bias correction; Trinormal model; MAR as-
sumption.
1 Introduction
The Receiver Operating Characteristic (ROC) curve analysis has been widely used as an
effective tool in measuring the accuracy of diagnostic tests in the two-class classification
problem. It shows a tradeoff between sensitivity and specificity by varying the cut-off point
through all possible values of the diagnostic marker. The ROC surface is a generalization of
the ROC curve which is intended to accommodate the problems of three-class classification
(Scurfield, 1996). Let X1, X2 and X3 be continuous measurements from three different
classes, X1 ∼ F1 are measurements from Class 1, X2 ∼ F2 are measurements from Class
2, and X3 ∼ F3 are measurements from Class 3. Suppose that the ordering of interest for
these three classes is X1 < X2 < X3. A decision rule that classifies subjects can be defined
by using two ordered threshold points c1 < c2, i.e. choose Class 1 when a measurement is
less than c1, choose Class 2 when it is between c1 and c2, and choose Class 3 otherwise.
This will result in three True Class Fractions (TCFs).
TCF1 = P(X1 ≤ c1) = F1(c1),
TCF2 = P(c1 ≤ X2 ≤ c2) = F2(c2)− F2(c1),
TCF3 = P(X3 > c2) = 1− F3(c2).
Varying c1 and c2 will give us a set of TCFs. To construct the ROC surface, plot
(TCF1,TCF2,TCF3) in a three-dimensional coordinate system. The functional form of
the ROC surface can be obtained by expressing TCF2 as a function of (TCF1,TCF3)
given by ROCs(TCF1,TCF3) = F2(F−13 (1−TCF3)− F2(F−11 (TCF1))) (Nakas and Yian-
noutsos, 2004).
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The Volume under the ROC Surface (VUS) was proposed as an important index for the
assessment of the diagnostic accuracy. This can be shown to be equal to P(X1 < X2 < X3),
(Mossman, 1999) and can also be calculated from the functional form of the ROC surface
as VUS =
∫ 1
0
∫ 1−F3(F−11 (p1))
0 ROCs(p1, p3)dp3dp1 (Nakas and Yiannoutsos, 2004).
The ROC surface has been used in diagnostic medicine when the disease has two phases,
for example, the early phase and late phase of a progressive disease. The symptoms in the
early phase may be mild and ignorable, while the late phase tends to have more severe
symptoms. Clearly there is an inherent ordering between healthy, early phase diseased
and late phase diseased. One example is the Alzheimer’s disease, which can be graded
low, intermediate and high according to the progress of the disease (Chi and Zhou, 2008).
Different medical treatments should be applied to different phases. For example, the
treatment for the late phase of disease can be expensive and may even be invasive to
patients, even surgeries may be included, while the treatment for the early phase can be
conservative. This necessitates the identification of the two phases of the disease and thus
leading to the consideration of three classes. We assume, without loss of generality, that
higher test values indicate a higher level of disease.
Many methods have been proposed for estimating the ROC surface. The naive method
is to replace the distribution functions in the functional form above by their empirical esti-
mates. Kang and Tian (2013) proposed using Gaussian kernel approaches for estimation of
distribution functions. A non-parametric Bayesian method of the ROC surface estimation
based on Finite Polya Tree prior distributions was proposed by Inácio et al. (2011).
A parametric method of estimating the ROC surface is based on the parametric tri-
normality assumption, that is, X1 ∼ N(µ1, σ21), X2 ∼ N(µ0, σ20), X3 ∼ N(µ2, σ22). Xiong et
al. (2006) obtained a closed form expression of the ROC surface under this assumption. If
the data mentioned are not normally distributed, Kang and Tian (2013) proposed the use
of Box-Cox to transform them to approximately normally distributed data.
Li and Zhou (2009) introduced a semi-parametric estimation of the ROC surface by
generalizing the method of the estimation of the ROC curve given by Hsieh and Turnbull
(1996) and Nze Ossima et al. (2013). They proposed two different estimation procedures
which are based on fitting an ROC surface with the trinormal parametric form using the
observed data.
In this paper, we propose a new semiparametric method for estimating the ROC surface.
This is a generalization of a Bayesian method for estimating the ROC curve using a rank-
based likelihood (BRL) introduced by Gu and Ghosal (2008). We assume that, under some
kind of unknown strictly monotone increasing transformation, the measurements follow
three different normal distributions. Since the rank is invariant under strictly monotone
increasing transformation, exploiting the rank-likelihood eliminates the need for specifying
a prior distribution on the unknown transformation, and enable us to construct a Bayesian
estimator of ROC surface.
We shall also consider the possibility of a verification bias in the data which widely
occur in practice but is scarcely considered in the existing literature. The true disease
status is verified only through the most accurate existing diagnostic test called the gold
standard test. However, this kind of tests may be expensive and even invasive, so the
common practice is to give this kind of verification test only to high-risk subjects which
can be identified through the result of the screening test. This leads to the problem of
estimating the ROC surface when not every patient’s true disease status (denoted as label
in this paper) is known to us. Because patients who are measured as low-risk are more
likely to have their labels missing since the gold standard test will be less likely to be used
for them, simply ignoring this missingness and estimating the ROC surface using only
existing labels may generate biased result. To deal with the missing label, the commonly
used missing at random (MAR) assumption (Little and Rubin, 1987) will be adopted. The
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assumption means that the probability of a subject being verified does not depend on the
disease status given the observed measurements. This is reasonable in this context since
the decision to obtain the gold standard test is generally made by looking at the diagnostic
test result and other external factors, while the effect of the true disease status is already
incorporated through its influence in diagnostic tests.
The existing literature is limited for this problem. Chi and Zhou (2008) considered
this problem for ordinal diagnostic tests and proposed the maximum likelihood estimator
for the ROC surface and the VUS. To Duc et al. (2016) considered this problem for
continuous diagnostic tests. They proposed several bias-corrected estimators of TCFs
and thus constructed a bias-corrected ROC surface. These methods are extensions of
Full Imputation (FI), Mean Score Imputation (MSI), Inverse Probability Weighted (IPW),
Semi-Parametric Efficient (SPE) estimators for the ROC curves in Alonzo and Pepe (2005).
They choose suitable parametric model to compute the probability of each individual
belonging to each class from verified subjects and applied this model to unverified subjects.
They also use suitable parametric model to compute the probability of verification. These
probabilities are used to adjust for the influence caused by missing labels.
Through some modification, our method for estimating the ROC surface can be ex-
tended to the setting under the verification bias. This can also be regarded as a gener-
alization of the ROC curve estimation under the verification bias proposed by Gu et al.
(2014).
The paper is organized as follows. The methodology is described in Section 2. We
first consider the setting without verification bias and then consider the case of verification
bias. A result describing the consistency of the posterior distribution obtained from the
rank likelihood is also presented. Extensive simulation studies are conducted in Section
3. The proposed Bayesian rank likelihood method is applied to real data set in Section 4.
The proof of the posterior consistency result is given in the appendix.
2 Methodology
2.1 Case without verification bias
2.1.1 Notation
Let us first consider the ROC surface estimation without verification bias. LetX, Y and Z
denote the diagnostic measurements from the healthy, level-1 diseased and level-2 diseased
groups in the study respectively. The number of observations from healthy group, level-1
diseased group and level-2 diseased group are denoted by by n0, n1 and n2 respectively,
and the total number of subjects is N = n0 + n1 + n2. The diagnostic measurements
for all N subjects in the study is denoted by S=(X,Y ,Z)=SN= (S1, ..., SN ) and their
true disease status is denoted by D = (D1, ..., DN ). Let 0 mean healthy, 1 mean level-1
diseased group and 2 mean level-2 diseased group for Di. So we have n0 =
∑N
i=1 1(Di = 0),
n1 =
∑N
i=1 1(Di = 1), and n2 =
∑N
i=1 1(Di = 2), where 1 stands for the indicator function.
With D and S, X,Y,Z can be redefined as X=Xn0=(X1, ..., Xn0)=(Si : Di = 0, i =
1, ..., N), Y =Yn1=(Y1, ..., Yn1)=(Si : Di = 1, i = 1, ..., N) and Z=Zn2=(Z1, ..., Zn2)=(Si :
Di = 2, i = 1, ..., N). Because we assume that there is no verification bias, the label reflects
exactly the true disease status, so we have L = (L1, ..., LN ) = D.
Since we assume that the trinomality assumption holds, under some strictly monotone
increasing transformation H, the transformed observations will be normally distributed
as described in (1) below. We denote the transformed measurements by E = H(X),
F = H(Y ), G = H(Z), and Q = H(S). Let S˜ and Q˜ stand for the order statistic
of S and Q respectively. Because H is a strictly monotone increasing function, we have
Q˜ = H(S˜). In addition, let L˜ and D˜ stand for the label and the true disease status
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corresponding to Q˜ respectively. The kth element of Q˜ and S˜ is denoted by Q˜k and
S˜k. The rank of S is defined as RN = R(S) = (R(S1), ..., R(SN )) = (RN1, ..., RNN ).
Let Φ(µ,σ)(·) denote the distribution function of N(µ, σ2) and φ(µ,σ)(·) denote its density
function. In addition, Φ(·) = Φ(0,1)(·), φ(·) = φ(0,1)(·).
2.1.2 Model
Let F0, F1 and F2 be the continuous cumulative distribution functions of the diagnostic
measurements for healthy group, level-1 disease group and level-2 disease group respec-
tively. That is, Si|{Di = 0} ∼ F0, Si|{Di = 1} ∼ F1, Si|{Di = 2} ∼ F2. Based on the
trinomality assumption, under some strictly monotone increasing transformation H, we
have:
Qi|Di = 0 i.i.d.∼ N(µ1, σ21), µ1 < 0;
Qi|Di = 1 i.i.d.∼ N(0, 1);
Qi|Di = 2 i.i.d.∼ N(µ2, σ22), µ2 > 0;
(1)
where Qi = H(Si).
The ROC surface under trinormality is given by (Xiong et al. 2006)
z =
[
Φ
(Φ−1(1− y) + d
c
)
− Φ
(Φ−1(x) + b
a
)]
+
, (2)
where
a = 1/σ1, b = µ1/σ1, c = 1/σ2, d = µ2/σ2. (3)
The volume under the ROC surface (VUS) is given by
VUS =
∫ ∞
−∞
Φ(as− b)Φ(−cs+ d)φ(s)ds. (4)
2.1.3 Prior distribution
In order to apply a Bayesian approach to estimate (µ1, σ1, µ2, σ2), or equivalently, (a, b, c, d),
we need to specify a prior distribution for those variables first. Because it is difficult to
specify a subjective prior for (µ1, σ1, µ2, σ2), here we follow Gu et al (2014) by choosing a
commonly used improper prior pi(µ1, σ1, µ2, σ2) ∝ σ−11 σ−12 for locational-scale parameters
but restricted to µ1 < 0, µ2 > 0.
2.1.4 Lemmas
Because H is a strictly monotone increasing transformation, R(Q), the ranks of Q and
L(Q), the labels of Q, preserve those of S. Therefore, we can define a set invariant under
the action of H as follows [6]:
Dobs = {(e, f, g) ∈ Rm+n : R(e,f , g) = R(S), L(e,f , g) = L(S)},
= {(e, f, g) ∈ Rm+n : ek < ek < ek, f l < fl < f l, gm < gm < gm,∀k, l,m,
L(e,f , g) = L(S)},
(5)
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where e = (e1, ..., en0),f = (f1, ..., fn1), g = (g1, ..., gn2), and
ek = max
i
{ei : RNi < RNk} ∨max
j
{fj : RNn0+j < RNk} ∨maxh {gh : RNn0+n1+h < RNk}
ek = min
i
{ei : RNi > RNk} ∧min
j
{fj : RNn0+j > RNk} ∧minh {gh : RNn0+n1+h > RNk}
f
l
= max
i
{ei : RNi < RNn0+l} ∨maxj {fj : RNn0+j < RNn0+l}
∨max
h
{gh : RNn0+n1+h < RNn0+l}
f l = min
i
{ei : RNi > RNn0+l} ∧minj {fj : RNn0+j > RNn0+l}
∧min
h
{gh : RNn0+n1+h > RNn0+l}
g
m
= max
i
{ei : RNi < RNn0+n1+m} ∨maxj {fj : RNn0+j < RNn0+n1+m}
∨max
h
{gh : RNn0+n1+h < RNn0+n1+m}
gm = min
i
{ei : RNi > RNn0+n1+m} ∧minj {fj : RNn0+j > RNn0+n1+m}
∧min
h
{gh : RNn0+n1+h > RNn0+n1+m}
for all k, i = 1, ..., n0; l, j = 1, ..., n1, m,h = 1, ..., n2. In the above, for am empty index set
the maximum is interpreted as −∞ and the minimum as ∞.
2.1.5 Likelihood and posterior distribution
First we consider the case without verification bias. Based on invariant set (5), a likelihood
is given by
P{(E,F,G) ∈ Dobs|µ1, σ1, µ2, σ2}
=P{(e, f, g) ∈ Rn0+n1+n2 : R(e, f, g) = R(S), L(e, f, g) = L(S)|µ1, σ1, µ2, σ2}.
(6)
Notice that without verification bias, L˜ = D˜, i.e., the labels reflect the true disease
status. Using Bayesian approach, the posterior sampling can be done by Gibbs sampling
as follows:
• Choose an initial value of (µ1, σ1, µ2, σ2). Generate initial value for (Q1, ..., QN )
according to (1), i.e., a sample which contains n0 many random variables from
N(µ1, σ
2
1), n1 many from N(0, 1) and n2 many from N(µ2, σ22), where n0, n1 and
n2 are the number of observations labeled as healthy, level-1 and level-2 diseased
groups.
• Iteratively execute the following steps:
1. Sample Q˜ sequentially conditional on (µ1, σ1, µ2, σ2) by
Q˜i|rest ∼

TN(µ1, σ
2
1, (Q˜i−1, Q˜i+1)), if D˜i = 0,
TN(0, 1, (Q˜i−1, Q˜i+1)), if D˜i = 1,
TN(µ2, σ
2
2, (Q˜i−1, Q˜i+1)), if D˜i = 2,
(7)
where i = 1, ..., N , Q˜0 = −∞, Q˜N+1 =∞.
2. Sample (µ1, σ1, µ2, σ2) conditional on Q˜ and D˜ by
µ1|rest ∼ TN(E¯n0 , σ21/n0, (−∞, 0)),
σ21|rest ∼ IG((n0 − 1)/2, (n0 − 1)s20/2),
µ2|rest ∼ TN(G¯n2 , σ22/n2, (0,∞)),
σ22|rest ∼ IG((n2 − 1)/2, (n2 − 1)s22/2),
(8)
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where IG stands for inverse gamma distribution, TN stands for truncated nor-
mal distribution, s20 =
∑n0
j=1(Ej − E¯n0)2/(n0 − 1), E¯n0 =
∑n0
j=1Ej/n0; s
2
2 =∑n2
j=1(Gj − G¯n2)2/(n2 − 1) and G¯n2 =
∑n2
j=1Gj/n2.
3. Calculate a, b, c, d according to (3) and VUS according to (4).
• Monitor the convergence through trace plot and discard all samples for a suitable
burn-in period, we obtain the estimates of the parameters (aˆ, bˆ, cˆ, dˆ) in the paramet-
ric ROC surface by averaging out the sample values of (a, b, c, d) in each iteration
respectively. The VUS is also estimated by averaging out the computed value of the
VUS in each MCMC iteration.
2.2 Case with verification bias
2.2.1 Notation
The notation is mostly the same as defined in Section 2.1.1, the only difference is with
the label. Under verification bias, only a fraction of patients have their true disease status
Di observed, i = 1, ..., N , so L = (L1, ..., LN ) is different from the previous case. With
verification bias, Li is defined by
Li =

0, if label is observed and Di = 0,
1, if label is observed and Di = 1,
2, if label is observed and Di = 2,
3, if label is not observed.
(9)
Thus Li indicates missing status as well as true disease status if the label is actually
observed.
Also we need to define some new variables to adjust for the verification bias. Let
n∗0, n∗1 and n∗2 stand for the number of observations labeled healthy, level-1 and level-
2 diseased groups respectively, i.e., n∗0 =
∑N
i=1 1(Li = 0), n
∗
1 =
∑N
i=1 1(Li = 1), and
n∗2 =
∑N
i=1 1(Li = 2), and put N
∗ = n∗0 +n∗1 +n∗2, the total number of observations having
labels. Note that X, Y and Z are not observable in this case since D is not observable.
In addition, we define the collection of unobserved labels as Dun = {Di : Li = 3, i ≤ N}
and the collection of observed labels as Dobs = {Di : Li = 0, 1 or 2, i ≤ N}.
2.2.2 Model
Assume that, the disease prevalence rates for level-1 and level-2 in the population are λ1
and λ2 respectively. So the true number of subjects in each group follows (n0, n1, n2) ∼
Mult(N, (λ0, λ1, λ2)), where Mult stands for the Multinomial distribution, λ0 = 1−λ1−λ2,
0 < λ1 < 1, 0 < λ2 < 1, and 0 < λ1 + λ2 < 1.
Because of the existence of the verification bias, we need to build a model for observing
actual labels. In a clinical practice, gold standard test will typically be prescribed according
to the screening test results. To be specific, a subject with higher risk of disease, suggested
by higher score in the diagnostic test, is more likely to be forwarded to the gold standard
test which is more thorough and more accurate. Because of this, missing completely at
random may not be appropriate. Simply ignoring unverified subjects will create bias to
our estimation. Here we follow Gu et al. (2014) and model this as missing at random. In
general, this model of verifying disease status can be represented as
P(Li 6= 3|Qi, Di) = g(Qi), (10)
for a given monotone increasing function g. Note that Qis here are not observed since we
can only observe Si = H(Qi) and H is unknown.
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In this paper, we consider two reasonable missing mechanisms following Gu and Ghoshal
(2014). The first model is proposed by Alonzo and Pepe (2005):
P(Li 6= 3|S) =
{
1, if S > S(p1N),
p2, otherwise.
(11)
Here, p1 and p2 are known probabilities. Since the ordering will not change after trans-
formation H, Q’s and S’s share the same ordering, so (11) can be considered as a special
case of (10).
g(Q) =
{
1, if Q > Q(p1N),
p2, if Q ≤ Q(p1N).
Another model exploits the probit link:
P(Li 6= 3|Qi) = Φ(α+ βQi) (12)
where α, β are known parameters with β > 0.
Notice that the case without the verification bias can be regarded as a special case of
(10) by simply setting g(Qi) = 1.
2.2.3 Prior distribution
We will apply a Bayesian approach to estimate (λ1, λ2, µ1, σ1, µ2, σ2), or equivalently,
(λ1, λ2, a, b, c, d). We still use the improper prior pi(µ1, σ1, µ2, σ2) ∝ σ−11 σ−12 for (µ1, σ1, µ2, σ2).
For disease prevalence rates, the prior is set to be (λ0, λ1, λ2) ∼ Dir(α0, α1, α2), where
Dir(·) stands for the Dirichlet distribution, α0, α1 and α2 are chosen according to the
mean and standard error from our prior knowledge.
2.2.4 Lemmas
The following lemmas are used to obtain posterior distribution and to prove the posterior
consistency. The proofs are deferred to the Appendix.
Lemma 2.1 Let D1, ..., DN be the true disease status corresponding to N subjects with
independent diagnostic measurements S1, ..., SN . Under the verification bias, assume that
(n0, n1, n2) ∼ Mult(N, (λ0, λ1, λ2)), and that (1) and (10) hold. Then we have
P(Di = 0|Qi = t, Li = 3) = P(Di = 0|Qi = t, Li 6= 3)
=
λ0φ(µ1,σ1)(t)
λ0φ(µ1,σ1)(t) + λ1φ(t) + λ2φ(µ2,σ2)(t)
,
P(Di = 1|Qi = t, Li = 3) = P(Di = 1|Qi = t, Li 6= 3)
=
λ1φ(t)
λ0φ(µ1,σ1)(t) + λ1φ(t) + λ2φ(µ2,σ2)(t)
,
P(Di = 2|Qi = t, Li = 3) = P(Di = 2|Qi = t, Li 6= 3)
=
λ2φ(µ2,σ2)(t)
λ0φ(µ1,σ1)(t) + λ1φ(t) + λ2φ(µ2,σ2)(t)
.
(13)
where Li is defined in (9).
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Remark For the case where there is no verification bias, i.e., Li 6= 3, then instead of (13)
we have
P(Di = 0|Qi = t) =
λ0φ(µ1,σ1)(t)
λ0φ(µ1,σ1)(t) + λ1φ(t) + λ2φ(µ2,σ2)(t)
,
P(Di = 1|Qi = t) = λ1φ(t)
λ0φ(µ1,σ1)(t) + λ1φ(t) + λ2φ(µ2,σ2)(t)
,
P(Di = 2|Qi = t) =
λ2φ(µ2,σ2)(t)
λ0φ(µ1,σ1)(t) + λ1φ(t) + λ2φ(µ2,σ2)(t)
.
(14)
Under verification bias, Lemma 2.1 shows that given Q, the random variable D and
the occurrence of {Li 6= 3} are independent. In addition, we can see that the expressions
above are free of g(·), which is the model of verification. Thus to calculate the posterior
distribution we do not actually need to know g. The monotonicity of g is needed because
Q is unobservable. Given monotonicity of g allows (10) to be presented in form of S.
Thus, this method is guarded against misspecification of the verification model. Thus,
our method is robust compared with other methods which focus on verification probability.
The following lemma has nothing to do with computing the posterior, but will be used
to study the consistency of posterior for large sample.
Lemma 2.2 Under verification bias, assume that (1) and (10) hold. Then the conditional
density of Q given that it is verified is given by
fQ(t|L 6= 3) =(1− λ∗1(µ1,σ1,µ2,σ2,g) − λ∗2(µ1,σ1,µ2,σ2,g))φ∗(µ1,σ1,g)(t) + λ∗1(µ1,σ1,µ2,σ2,g)φ∗(g)(t)
+ λ∗2(µ1,σ1,µ2,σ2,g)φ
∗
(µ1,σ1,g)
(t),
(15)
where λ∗1(µ1,σ1,µ2,σ2,g), λ
∗
2(µ1,σ1,µ2,σ2,g)
and φ∗(µ,σ,g)(t) are defined by
λ∗1(µ1,σ1,µ2,σ2,g) =
λ1
∫
g(s)φ(s)ds∫
g(s){(1− λ1 − λ2)φ(µ1,σ1)(s) + λ1φ(s) + λ2φ(µ2,σ2)(s)}ds
,
λ∗2(µ1,σ1,µ2,σ2,g) =
λ2
∫
g(s)φ(µ2,σ2)(s)ds∫
g(s){(1− λ1 − λ2)φ(µ1,σ1)(s) + λ1φ(s) + λ2φ(µ2,σ2)(s)}ds
,
φ∗(µ,σ,g)(t) =
g(t)φ(µ,σ)(t)∫
g(s)φ(µ,σ)(s)ds
,
(16)
and φ∗(g)(t) stands for φ
∗
(0,1,g)(t).
2.2.5 Posterior distribution
Our method is still based on the rank-based partial likelihood on the invariant set (5).
However, we need to do some adjustment since now D˜ is no longer equal to L˜ and is only
partially known. More specifically, we have Di = Li where Di ∈ Dobs, but Di ∈ Dun
are not observable and are unknown to us. Thus we need to apply data augmentation
technique to get Q˜ andDun, and then implement Gibbs sampling to compute the posterior
distribution conditional on the remaining variables. The computing algorithm is as follows:
• Initialize missing labels Di ∈ Dun using (N −N∗) independent Mult(1, (λ0, λ1, λ2))
variables, where (λ0, λ1, λ2) is generated from Dir(α0, α1, α2) to form an initial com-
plete D˜. The number of subjects in each class can be calculated as n′0 = ΣNi=11{D˜i =
0}, n′1 = ΣNi=1m1{D˜i = 1} and n′2 = ΣNi=11{D˜i = 2}
• Choose an initial value of (µ1, σ1, µ2, σ2). Generate an initial value for (Q1, ..., QN )
according to (1), i.e., a sample which contains n′0 many random variables from
N(µ1, σ
2
1), n′1 many from N(0, 1) and n′2 many from N(µ2, σ22).
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• Iteratively execute the following steps:
1. Sample Q˜ sequentially conditional on (µ1, σ1, µ2, σ2) by
Q˜i|rest ∼

TN(µ1, σ
2
1, (Q˜i−1, Q˜i+1)), if D˜i = 0,
TN(0, 1, (Q˜i−1, Q˜i+1)), if D˜i = 1,
TN(µ2, σ
2
2, (Q˜i−1, Q˜i+1)), if D˜i = 2,
(17)
where i = 1, ..., N , Q˜0 = −∞, Q˜N+1 =∞.
2. Sample (µ1, σ1, µ2, σ2) conditional on Q˜ and D˜ by
µ1|rest ∼ TN(E¯n′0 , σ21/n′0, (−∞, 0)),
σ21|rest ∼ IG((n′0 − 1)/2, (n′0 − 1)s20/2),
µ2|rest ∼ TN(G¯n′2 , σ22/n′2, (0,∞)),
σ22|rest ∼ IG((n′2 − 1)/2, (n′2 − 1)s22/2),
(18)
where n′0 =
∑N
i=1{1(D˜i = 0, L˜i = 3)+1(L˜i = 0)}, s20 =
∑n′0
j=1(Ej−E¯n′0)2/(n′0−
1), E¯n′0 =
∑n′0
j=1Ej/n
′
0; n′2 =
∑N
i=1{1(D˜i = 2, L˜i = 3) + 1(L˜i = 2)}, s22 =∑n′2
j=1(Gj − G¯n′2)2/(n′2 − 1) and G¯n′2 =
∑n′2
j=1Gj/n
′
2.
3. Sample (λ0, λ1, λ2) given the rest by
(λ0, λ1, λ2)|rest ∼ Dir(α0 + n′0, α1 + n′1, α2 + n′2), (19)
where n′1 =
∑N
i=1{1(D˜i = 1, L˜i = 3) + 1(L˜i = 1)}.
4. Sample the augmentation variable D˜i ∈Dun by(
1{D˜i = 0},1{D˜i = 1},1{D˜i = 2}
)
|rest ∼
Mult
(
1,
(
λ0φ(µ1,σ1)(Q˜i)
λ0φ(µ1,σ1)(Q˜i) + λ1φ(Q˜i) + λ2φ(µ2,σ2)(Q˜i)
,
λ1φ(Q˜i)
λ0φ(µ1,σ1)(Q˜i) + λ1φ(Q˜i) + λ2φ(µ1,σ1)(Q˜i)
,
λ2φ(µ2,σ2)(Q˜i)
λ0φ(µ1,σ1)(Q˜i) + λ1φ(Q˜i) + λ2φ(µ2,σ2)(Q˜i)
))
(20)
5. Calculate a, b, c, d according to (3) and VUS according to (4).
• Monitor the convergence through trace plot and discard all samples for a suitable
burn-in period, we obtain the estimates of the parameters (aˆ, bˆ, cˆ, dˆ) in the paramet-
ric ROC surface by averaging out the sample values of (a, b, c, d) in each iteration
respectively. The VUS is also estimated by averaging out the computed value of the
VUS in each MCMC iteration.
2.3 Consistency of the posterior distributions
As we already showed that the case without verification bias can be regarded as a special
case of under verification bias model by simply setting g(Qi) = 1 in (10). Thus we only
need to show posterior consistency under verification bias.
Let ν denote the Lebesgue norm and pi denote the prior density for (µ1, σ1, µ2, σ2)
with respect to ν. Let (µ∗1, σ1∗, µ∗2, σ∗2) be the true value of (µ1, σ1, µ2, σ2). We shall show
that the posterior distribution Π(·|R(S),L) of (µ1, σ1, µ2, σ2) generally concentrates near
(µ∗1, σ∗1, µ∗2, σ∗2) for large sample size.
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Theorem 2.3 Assume (1) and (10) hold for a monotone increasing function g: R to (0, 1).
Let pi(µ1, σ1, µ2, σ2) > 0 a.e. [ν]. R− × R+ × R+ × R+. Then for (µ∗1, σ∗1, µ∗2, σ∗2) a.e. [ν],
and any neighborhood U0 of (µ∗1, σ1∗, µ∗2, σ∗2) , we have that
lim
N→∞
Π((µ1, σ1, µ2, σ2) ∈ U0|R(S),L) = 1, a.s. (21)
with respect to [P∞µ∗1,σ1∗,µ∗2,σ∗2 ,g,H ], the true joint distribution of all ranks and labels.
We prove that this theorem using a general posterior consistency theorem by Doob. The
complete proof is given in appendix. The main idea is that we show that the parameters
can be expressed as a function of the observations and then apply Doob’s theorem to show
posterior consistency. The theorem provides a theoretical justification of our method from
the frequentist point of view.
3 Simulation
3.1 Without verification bias
In this simulation, set n0 = n1 = n2 = n, so we generate N = 3n data in total with n data
from each category as the unobserved after-transformation measurements, where n is set
to be 50 and 100. and the true underlying normal distribution is taken to be N(−1.8, 1.5),
N(0, 1) and N(2, 2), i.e., the true value for (a, b, c, d) in (2) is (0.667,−1.2, 0.5, 1) and the
true VUS=0.671. Also we consider two different true transformations H here, the first
is logarithm transformation, i.e., H(x) = log(x); the second is logit transformation, i.e.,
H(x) = log(x/(1− x)). We first simulate unobserved after-transformation measurements,
and then use the inverse of the true transformation to get the raw data that we observe in
reality.
For comparison purpose, we compare our methods (BRL) to existing state-of-art meth-
ods. The first method we consider is based on eliminating the unknown transformation
H. Here, we follow Kang and Tian (2013) to use the Box-Cox transformation. Notice that
one of the first true transformations we choose here, i.e., the logarithmic transformation,
belongs to the Box-Cox transformation family. After Box-Cox transformation, we use the
maximum likelihood method to estimate parameters following the idea of Xiong et al.
(2006).
Also we compare BRL to two other semiparametric methods (denoted here by Semi1
and Semi2) proposed by Li and Zhou (2009). The simulation results are shown in Tables 1
and 2. We calculate the bias and the MSE of the estimates of the parameters and also the
bias and the MSE of the estimates of the volume under the surface (VUS). The bias and
the MSE shown in the table are their true values multiplied by 102 and the Monte Carlo
standard error for each estimate is shown in parentheses below (also multiplied by 102).
All the estimates are based on 100 simulated data sets. For each data set, our BRL
method is calculated with 90000 Gibbs samples (100000 MCMC iterations after 10000
samples used for burn-in).
Notice that, BRL has nothing to do with the true transformation since we only consider
the rank information given by the data. So it is expected that the simulation result applying
to these two different data sets will be almost the same, except for the difference due to
sampling.
From Table 1 and Table 2, it is not surprising to find that when the true transformation
belongs to the Box-Cox family, the Box-Cox method performs best in terms of both bias and
MSE. However, when the true transformation is no longer from this family, the performance
of Box-Cox is not satisfactory, indicating that this method is not robust under the proposed
transformation. BRL method has lower bias and MSE of estimates of the parameters and
VUS in this case compared with other methods except for the parameter a.
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Table 1: Bias (×102) and MSE (×102) for estimates of parameter values without verifica-
tion bias
n = 50 n = 100
BRL Box-Cox Semi1 Semi2 BRL Box-Cox Semi1 Semi2
true transformation=log(x)
a
bias −19.5 6.0 −15.3 −12.2 −10.7 4.6 −16.1 −12.9
(1.6) (1.3) (1.3) (1.4) (0.8) (0.9) (0.9) (1.4)
MSE 6.4 2.0 4.0 3.4 1.3 1.1 3.5 3.7
(0.7) (0.4) (0.4) (0.3) (0.2) (0.2) (0.3) (0.3)
b
bias 4.0 −0.1 26.6 27.1 1.3 −4.6 19.2 21.7
(2.2) (2.4) (2.0) (1.7) (1.3) (1.7) (1.4) (1.2)
MSE 4.8 5.6 11.0 10.2 1.7 2.9 5.8 6.3
(0.8) (0.8) (1.2) (1.1) (0.2) (0.5) (0.5) (0.5)
c
bias −14.4 −3.6 17.4 17.0 −6.0 −2.8 21.4 20.6
(1.2) (1.0) (1.3) (1.3) (0.7) (0.7) (1.5) (1.4)
MSE 3.6 1.2 4.7 4.6 0.9 0.6 6.9 6.1
(0.4) (0.2) (0.5) (0.6) (0.1) (0.1) (0.9) (0.8)
d
bias −3.3 −2.8 28.9 24.1 −1.2 −0.2 27.8 24.5
(1.8) (1.9) (2.0) (1.9) (1.4) (1.4) (1.9) (1.7)
MSE 3.3 3.6 12.5 9.4 1.9 2.1 11.3 8.9
(0.4) (0.5) (1.4) (1.2) (0.3) (0.4) (1.3) (1.1)
true transformation=log(x/(1− x))
a
bias −16.0 25.5 −15.6 −12.1 −8.7 28.2 −18.1 −13.5
(1.4) (1.7) (1.3) (1.7) (1.0) (1.3) (0.8) (1.3)
MSE 4.4 9.3 4.1 4.2 1.8 9.7 4.0 3.6
(0.5) (1.0) (0.5) (0.4) (0.3) (8.0) (0.3) (0.3)
b
bias 0.3 −14.1 23.5 26.3 0.8 −22.3 22.1 23.7
(2.1) (3.1) (2.1) (1.7) (1.6) (2.5) (1.4) (1.2)
MSE 4.3 11.6 9.9 9.7 2.6 10.9 6.8 7.2
(0.6) (2.0) (1.1) (1.1) (0.6) (1.7) (0.7) (0.6)
c
bias −10.9 38.1 18.6 17.2 −5.1 36.9 19.5 19.4
(1.1) (1.5) (1.3) (1.4) (0.9) (1.1) (1.3) (1.2)
MSE 2.4 16.7 5.2 5.1 1.0 14.8 5.7 5.3
(0.3) (1.4) (0.6) (0.7) (0.1) (0.9) (0.8) (0.6)
d
bias −1.6 9.0 28.9 22.5 1.3 10.5 27.0 24.1
(2.0) (3.4) (1.8) (1.7) (1.5) (2.5) (1.8) (1.6)
MSE 4.1 12.1 11.7 7.8 2.3 7.1 10.7 8.5
(0.5) (3.0) (1.1) (0.8) (0.3) (1.5) (1.2) (1.0)
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Table 2: Bias (×102) and MSE (×102) for estimates of VUS without verification bias
BRL Box-Cox Semi1 Semi2 BRL Box-Cox Semi1 Semi2
true transformation=log(x)
n = 50 n = 100
VUS
bias 1.0 −1.6 −0.9 −2.0 0.9 0.1 0.4 −0.8
(0.5) (0.5) (0.5) (0.5) (0.3) (0.3) (0.3) (0.4)
MSE 0.23 0.23 0.27 0.26 0.12 0.11 0.12 0.20
(0.03) (0.04) (0.03) (0.04) (0.02) (0.02) (0.17) (0.04)
true transformation=log(x/(1− x))
n = 50 n = 100
VUS
bias −1.5 −4.3 −0.3 −2.1 1.1 −2.4 0.2 −1.1
(0.5) (0.6) (0.5) (0.5) (0.3) (0.4) (0.4) (0.5)
MSE 0.30 0.53 0.22 0.30 0.12 0.21 0.14 0.22
(0.04) (0.07) (0.03) (0.05) (0.02) (0.03) (0.03) (0.04)
Table 3: Different data settings
(µ1, σ1, µ2, σ2) (a, b, c, d) VUS
(−1.8, 1.5, 2, 2) (0.667,−1.2, 0.5, 1) 0.671
(−2.3, 1, 2, 1) (1,−2.3, 1, 2) 0.870
3.2 With verification bias
3.2.1 Under trinormal assumption
In this simulation, set n0 = n1 = n2 = n, so we generate N = 3n data in total with n data
from each category. We consider two different trinormal distributions settings. The three
distributions are N(µ1, σ21), N(0, 1) and N(µ2, σ22), after transformation. The parameters
(a, b, c, d) and the VUS can be uniquely determined by (µ1, σ1, µ2, σ2) according to (3) and
(4).
Within each simulation setting, two verification mechanisms based on verification mod-
els (11) for threshold value and (12) for probit regression model, are used to generate the
data with verification bias, which somewhat resemble the data we observe in reality. For
the former case, p1 is taken to be 0.8 and p2 is taken to be 0.4 in (11), which will give an
average of 48% missing labels. For the latter case, β is fixed to be 1 and α is adjusted to
be 0.106, 0.170 and 0.189 to achieve 48% missing labels for each of the cases mentioned
above. BRL estimates are obtained by 90000 Gibbs samples, (100000 MCMC iterations
after 10000 iterations used for burn-in). In total 100 datasets are simulated for the study.
For threshold missing scheme (11), n is set to be 100 and 200, while for probit missing
scheme (12), none of the methods considered give results for n = 100, suggesting that at
such a missing rate the number of observations may be insufficient. So we only consider
n = 200 for this missing mechanism.
There are very limited papers dealing with the problem when missing labels are involved
in estimating the ROC surface. We compare our method to FI, MSI, IPW and SPE method
proposed by To Duc et al. (2016). We use a multivariate logistic model to estimate the
true disease rate and a logistic model to estimate verification rate in order to apply those
methods. Because these methods can only give estimate at a point, we consider fitting a
surface to those points that has the form under trinormality assumption, given by (2). We
start with a grid and find the parameters that minimize the sum of squared distance for
every point on the grid. The comparison of the estimates are given in the tables below.
We also compare those methods in terms of the estimated accuracy of VUS. Notice that
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for the VUS of FI, MSI and IPW, we use the calculation of VUS given in To Duc et al.
(2016) instead of just plugging in the parameter estimates in (4).
From Tables 4 and 6, we can see that BRL performs consistently better in term of
accuracy in almost all of the cases considered above for parameter estimates. The estimates
of the parameter a from BRL sometimes have more bias and larger MSE compared with
other methods. The estimates of the parameter b sometimes have more bias but is more
accurate in terms of MSE. The estimates of the parameters c and d from BRL are more
accurate in terms of both bias and MSE. From Tables 5 and 7, we see that BRL may have
larger bias but always has the smallest MSE on estimating VUS. To sum up, BRL has the
best performance overall. It is also worth mentioning that when the sample size increases,
accuracy of all methods considered improved, as expected. The improvement is the biggest
for BRL.
3.2.2 Departure from trinormality assumption
It is important to study the performance of our method when the data does not satisfy the
trinormality assumption. Here we generate (X1, ..., Xn0) independently from Beta(3, 5),
(Y1, ..., Yn1) independently from Beta(2, 2), (Z1, ..., Zn2) independently from Beta(5, 3),
where n0 = n1 = n2 = n = 200. The corresponding VUS = 0.35815 and 100 simulated
data sets are used in the study. For the verification bias models, we use p1 = 0.8 and
p2 = 0.4 in (11), and α = 0.01 and β = 0.07 in (12), both of them give missing rates
approximately 48%. BRL estimates are obtained by 90000 Gibbs samples, (100000 MCMC
iterations after 10000 iterations used for burn-in).
We see from Table 8 that BRL estimates are more accurate than other methods for the
VUS especially in term of the MSE and under the threshold missing mechanism. Under the
probit model, BRL has slightly more bias and larger MSE compared with IPW and SPE
but the difference is insignificant. The simulation results show that BRL is unexpectedly
robust against departure from trinormality.
3.2.3 Departure from the MAR assumption
When the MAR assumption failed, the verification probability is no longer independent of
disease status conditional on observed values. Thus the model we have in (10) is no longer
correct. More precisely, we will have
P(Li 6= 3|Qi, Di = 0) = g0(Qi),
P(Li 6= 3|Qi, Di = 1) = g1(Qi),
P(Li 6= 3|Qi, Di = 2) = g2(Qi),
(22)
then as in the proof of Lemma 2, it follows that
P(Di = 0|Qi = t, Li = 3) = P(Di = 0|Qi = t, Li 6= 3)
=
λ0g0(t)φ(µ1,σ1)(t)
λ0g0(t)φ(µ1,σ1)(t) + λ1g1(t)φ(t) + λ2g2(t)φ(µ2,σ2)(t)
,
P(Di = 1|Qi = t, Li = 3) = P(Di = 1|Qi = t, Li 6= 3)
=
λ1g1(t)φ(t)
λ0g0(t)φ(µ1,σ1)(t) + λ1g1(t)φ(t) + λ2g2(t)φ(µ2,σ2)(t)
, ,
P(Di = 2|Qi = t, Li = 3) = P(Di = 2|Qi = t, Li 6= 3)
=
λ2g2(t)φ(µ2,σ2)(t)
λ0g0(t)φ(µ1,σ1)(t) + λ1g1(t)φ(t) + λ2g2(t)φ(µ2,σ2)(t)
.
(23)
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Table 4: Bias (×102) and MSE (×102) for estimates of parameter values under trinormality,
with verification bias generated using the threshold model
n = 100 n = 200
BRL FI MSI IPW BRL FI MSI IPW
(a, b, c, d) = (0.667,−1.2, 0.5, 1)
a
bias −19.5 31.4 10.9 −1.9 −8.2 30.8 10.0 −3.4
(1.6) (0.4) (1.0) (1.9) (0.8) (0.3) (0.7) (1.0)
MSE 6.5 10.0 2.2 3.5 1.4 9.6 1.5 1.0
(0.8) (0.2) (0.3) (1.5) (0.2) (0.2) (0.1) (0.2)
b
bias −4.0 3.0 12.8 −9.3 −0.7 0.7 12.5 −7.6
(2.1) (2.0) (1.9) (1.9) (1.5) (1.5) (1.4) (1.6)
MSE 4.7 4.0 5.0 4.5 2.2 2.3 3.6 3.0
(1.5) (0.5) (0.6) (1.0) (0.3) (0.3) (0.4) (0.5)
c
bias −13.8 22.1 28.3 12.4 −5.6 25.0 27.1 8.1
(1.3) (1.6) (2.4) (3.9) (0.8) (1.3) (2.0) (2.2)
MSE 3.5 7.4 13.7 16.8 0.9 7.8 11.5 5.3
(0.4) (0.6) (2.0) (9.9) (0.1) (0.5) (1.5) (2.0)
d
bias −5.3 12.1 22.1 16.3 −2.8 18.7 24.5 17.8
(1.9) (2.7) (3.8) (5.6) (1.5) (2.2) (2.7) (3.4)
MSE 3.8 8.9 18.9 33.8 2.2 8.4 13.2 14.7
(0.5) (2.0) (3.9) (17.6) (0.4) (1.0) (2.2) (6.5)
(a, b, c, d) = (1,−2.3, 1, 2)
a
bias −10.5 3.1 7.8 7.2 −2.5 0.4 3.7 4.5
(2.7) (0.8) (1.4) (3.5) (1.8) (0.4) (1.1) (2.9)
MSE 8.4 0.7 2.6 12.8 3.3 0.2 1.4 8.6
(1.2) (0.1) (0.4) (2.4) (0.5) (0.1) (0.3) (2.6)
b
bias 3.0 −7.1 −9.0 −8.8 −1.2 0.6 2.4 −0.1
(3.2) (3.6) (3.8) (5.2) (2.7) (2.4) (2.6) (3.5)
MSE 10.3 13.5 15.2 27.9 7.4 5.9 6.6 11.9
(1.5) (2.2) (2.4) (7.6) (1.1) (1.0) (1.0) (2.9)
c
bias −7.6 9.9 11.1 18.9 −1.7 11.1 9.4 23.1
(2.6) (1.8) (3.1) (5.9) (1.6) (1.6) (2.4) (4.6)
MSE 7.5 4.1 10.9 37.6 2.5 3.8 6.7 26.7
(1.3) (0.8) (2.1) (10.0) (0.4) (0.8) (1.2) (5.7)
d
bias −2.8 18.8 9.9 32.6 0.7 22.0 13.9 48.3
(4.2) (4.1) (5.0) (8.6) (2.9) (3.5) (4.5) (8.0)
MSE 18.0 19.9 25.7 83.1 8.2 16.7 22.1 86.5
(4.1) (4.7) (5.4) (22.4) (1.2) (3.8) (3.8) (21.1)
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Table 5: Simulation result for the VUS under trinormality, with verification bias generated
using the threshold model
n = 100
BRL FI MSI IPW SPE
(a, b, c, d) = (0.667,−1.2, 0.5, 1),VUS = 0.671
VUS
bias 1.9 −1.4 0.1 6.2 1.4
(0.4) (0.6) (0.5) (0.5) (0.5)
MSE 0.19 0.34 0.26 0.64 0.26
(0.03) (0.05) (0.03) (0.06) (0.03)
(a, b, c, d) = (1,−2.3, 1, 2),VUS = 0.870
VUS
bias 0.1 0.8 0.7 2.7 0.5
(0.3) (0.2) (0.26) (0.3) (0.3)
MSE 0.08 0.07 0.07 0.14 0.08
(0.01) (0.01) (0.01) (0.01) (0.01)
n = 200
BRL FI MSI IPW SPE
(a, b, c, d) = (0.667,−1.2, 0.5, 1),VUS = 0.671
VUS
bias 0.6 −1.6 −0.2 6.4 1.1
(0.3) (0.4) (0.3) (0.3) (0.3)
MSE 0.12 0.17 0.12 0.52 0.12
(0.02) (0.34) (0.02) (0.05) (0.02)
(a, b, c, d) = (1,−2.3, 1, 2),VUS = 0.870
VUS
bias 0.1 0.4 0.3 2.5 0.3
(0.2) (0.2) (0.2) (0.2) (0.002)
MSE 0.05 0.05 0.05 0.11 0.06
(< 0.01) (0.01) (0.01) (0.01) (0.01)
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Table 6: Bias (×102) and MSE (×102) for estimates of parameter values under trinormality,
with verification bias generated using the probit model, n = 200
BRL FI MSI IPW
(a, b, c, d) = (0.667,−1.2, 0.5, 1)
a
bias −17.3 29.6 22.8 1.8
(1.0) (0.2) (0.5) (1.9)
MSE 4.1 8.8 5.5 3.6
(0.4) (0.1) (0.2) (0.9)
b
bias −11.7 40.7 42.2 33.6
(1.3) (2.7) (2.6) (2.6)
MSE 2.9 23.7 24.3 18.0
(0.4) (2.7) (2.7) (2.7)
c
bias −9.6 35.6 53.9 8.1
(1.0) (2.8) (3.7) (1.6)
MSE 1.9 20.3 42.4 3.2
(0.2) (5.9) (4.5) (0.6)
d
bias −12.5 61.2 69.6 −1.5
(1.8) (6.1) (6.1) (3.1)
MSE 4.9 73.9 8.5 9.3
(0.6) (27.1) (13.2) (1.6)
(a, b, c, d) = (1,−2.3, 1, 2)
a
bias −10.3 2.0 4.1 −1.5
(2.7) (0.6) (1.9) (3.3)
MSE 8.3 0.4 3.7 10.6
(1.0) (0.1) (0.6) (2.6)
b
bias −6.6 −11.5 −7.9 32.1
(3.2) (3.4) (4.2) (3.7)
MSE 10.8 12.8 18.3 23.8
(3.3) (2.2) (3.0) (2.5)
c
bias −9.5 8.9 1.7 −3.1
(1.5) (2.1) (2.7) (2.1)
MSE 3.1 5.1 7.4 4.6
(0.5) (1.6) (1.8) (0.7)
d
bias −12.7 18.3 0.6 −13.4
(2.3) (4.2) (5.0) (4.4)
MSE 6.9 20.8 25.2 20.6
(1.0) (5.8) (6.4) (3.7)
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Table 7: Bias (×102) and MSE (×102) for estimates of VUS under trinormality, with
verification bias generated using the probit model, n = 200
BRL FI MSI IPW SPE
(a, b, c, d) = (0.667,−1.2, 0.5, 1), VUS=0.671
VUS
bias 1.2 −5.4 −5.3 −8.2 −6.4
(0.4) (0.7) (0.7) (1.2) (1.1)
MSE 0.16 0.79 0.78 2.1 1.5
(0.02) (0.14) (0.15) (0.42) (0.29)
(a, b, c, d) = (1,−2.3, 2, 1), VUS=0.870
VUS
bias 0.2 0.5 0.5 −2.8 0.6
(0.2) (0.2) (0.2) (0.6) (0.3)
MSE 0.06 0.05 0.05 0.49 0.11
(0.01) (0.01) (0.01) (0.11) (0.02)
Table 8: Bias (×102) and MSE (×102) for estimates of VUS when departing from the
trinormality assumption, n = 200
Threshold
BRL FI MSI IPW SPE
VUS
bias −0.3 4.6 2.4 1.2 −1.4
(0.2) (0.2) (0.3) (0.3) (0.3)
MSE 0.03 0.28 0.12 0.13 0.13
(0.01) (0.02) (0.02) (0.02) (0.02)
Probit
BRL FI MSI IPW SPE
VUS
bias −1.6 4.8 2.5 0.1 0.1
(0.2) (0.3) (0.3) (0.3) (0.3)
MSE 0.08 0.30 0.14 0.10 0.10
(0.01) (0.03) (0.02) (0.01) (0.01)
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Table 9: Bias (×102) and MSE (×102) for estimates of parameter estimates when departing
from the MAR assumption, n = 200
Threshold Probit
BRL FI MSI IPW BRL FI MSI IPW
a bias −12.3 30.3 21.6 −8.9 −10.6 31.6 20.1 −1.7
(1.3) (0.3) (0.6) (1.5) (1.0) (0.3) (0.7) (1.2)
MSE 3.1 9.2 5.1 3.2 2.9 10.0 4.5 1.3
(0.4) (0.2) (0.3) (0.4) (0.3) (0.2) (0.3) (0.2)
b bias 1.8 38.0 41.7 −19.3 5.5 30.4 35.3 37.2
(1.4) (1.8) (1.7) (3.5) (1.5) (1.9) (1.7) (1.7)
MSE 2.1 17.7 20.3 15.9 2.6 12.9 15.4 16.9
(0.3) (1.4) (1.4) (2.1) (0.4) (1.3) (1.3) (1.5)
c bias −23.4 30.4 37.1 −15.0 −11.8 28.8 34.3 5.9
(0.7) (1.7) (3.2) (0.9) (0.8) (1.3) (2.4) (1.4)
MSE 6.0 12.1 24.2 3.0 2.1 10.1 17.4 2.4
(3.7) (1.4) (5.6) (0.3) (0.2) (0.7) (1.9) (0.6)
d bias −43.3 37.2 51.5 −50.3 −23.0 19.6 24.7 −19.5
(1.5) (3.0) (6.6) (3.8) (1.5) (2.3) (3.1) (1.9)
MSE 20.9 22.8 69.3 39.8 7.6 9.3 15.6 7.5
(1.3) (3.2) (23.7) (5.1) (0.7) (1.1) (2.6) (0.8)
The true normal distributions considered here are N(µ1, σ21), N(0, 1) and N(µ2, σ22),
where (µ1, σ1, µ2, σ2) = (−1.8, 1.5, 2, 2). We consider two cases when the MAR assumption
fails. Let λ0 = λ1 = λ2 = 1/3, to achieve 48% verification probability, i.e. P(Li 6= 3) =
0.48, let P(Li 6= 3|Di = 0) = 0.72, P(Li 6= 3|Di = 1) = 0.48 and P(Li 6= 3|Di = 2) = 0.24.
Consider two cases here.
1. Let g(Q; p1, p2) =
{
1, if Q > Q(p1N),
p2, if Q ≤ Q(p1N).
The verification model for healthy group is g0(Q) = g(Q; 0.8, 0.1); the verification
model for level-1 disease is g1(Q) = g(Q; 0.6, 0.2); the verification model for level-2
disease is g2(Q) = g(Q; 0.4, 0.4).
2. Let g(Q;α, β) = Φ(α+ βQ).
The verification model for healthy group is g0(Q) = g(Q; 0.217, 0.5); the verification
model for level-1 disease is g1(Q) = g(Q; 0.052, 0.3); the verification model for level-2
disease is g2(Q) = g(Q; 0.334, 0.2).
Here n0 = n1 = n2 = n is set to be 200. Again we simulate 100 data sets for the study,
and BRL estimates are obtained by 90000 Gibbs samples, (100000 MCMC iterations after
10000 iterations used for burn-in).
It is expected that the bias and MSE are larger compared with the situation under
MAR mechanism, which is indeed shown in Tables 9 and 10. We also see that still BRL
has more accurate estimates of parameters. For VUS, under the threshold model, BRL
has slightly more bias and larger MSE compared with FI and MSI, but the difference is
insignificant, while under probit model BRL still has the best performance. Thus BRL is
robust against departure from the MAR assumption.
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Table 10: Bias (×102) and MSE (×102) for estimates of the VUS when departing from the
MAR assumption, n = 200
Threshold
BRL FI MSI IPW SPE
VUS
bias −8.3 −6.8 −6.1 −6.5 −5.4
(0.3) (0.5) (0.5) (1.2) (1.7)
MSE 0.79 0.70 0.59 1.89 3.01
(0.06) (0.07) (0.06) (0.37) (0.78)
Probit
BRL FI MSI IPW SPE
VUS
bias −4.5 −7.9 −6.9 −9.8 −7.7
(0.4) (0.4) (0.4) (0.4) (0.4)
MSE 0.34 0.80 0.63 1.13 0.77
(0.04) (0.08) (0.06) (0.09) (0.08)
4 Real data analysis
As an illustration of the application of our method, we apply this to a real data set on the
diagnosis of epithelial ovarian cancer (EOC). This data from the SPORE/Early Detection
Network/Prostate, Lung, Colon, and Ovarian Cancer Ovarian Validation Study is available
to public.1 This data is also partially available in R-package bcROCsurface by To Duc
(2017) as an implementation of their bias-corrected methods for the ROC surface. We
follow their setting by using this data set and compare their methods.
This data set is used for evaluating the performance of several biomarkers in diagnosis
of EOC. There are three classes included in this data set, i.e., benign disease, early stage
and late stage cancer. We want to know which biomarkers are the most informative on
their own in prediction on these three classes. The two particular biomarkers we compare
in this example are CA125 and CA153, measured at Havard laboratories. We have 134
patients with benign disease, 67 in early stage and 77 in late stage. Since all of our samples
are verified, there is no verification bias issue here. So we will apply our BRL method on
without verification bias setting and then compare this to empirical estimates.
To illustrate the verification bias case, To Duc et al. (2016) simulated a verification pro-
cess, i.e., P(Li = 3) = 0.05+0.351(CA125i > 0.87)+0.251(CA153i > 0.3)+0.351(Agei >
45). This process leads to 63.4% patients selected to undergo disease verification. We
compare BRL with FI, MSI, IPW and SPE, where a logistic model is used to estimate the
true disease rate and a logistic model to estimate verification rate as well.
First we look at the ROC surface of CA125. In Table 11 we give the estimates of
parameters of the ROC surface for BRL applying on the full data and then to the data
obtained under verification bias. It can be seen from this table that the parameter estimates
using BRL in those two cases are similar, with b having the biggest difference of around
0.2. Also the standard deviation of parameter estimates increased from the full data to
the data under verification bias, which is expected.
In Table 12, we give the estimates of the VUS by empirical and BRL methods using
the full data and BRL, FI, MSI, IPW and SPE using the data with verification bias (BRL
method applied on the full data is denoted by BRL full while BRL method applied on
the data with verification bias is denoted by BRL vb). The BRL methods are based on
250000 iterations as the chain has 300000 iterations after 50000 iterations as burn-in. The
estimates of the VUS are similar using all of those methods, with BRL applying to data
1https://edrn.nci.nih.gov/protocols/119-spore-edrn-pre-plco-ovarian-phase-ii-validation
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Table 11: Parameter estimates from BRL methods for CA125
full with verification bias
estimate sd 95% C.I. estimates sd 95% C.I.
a 1.151 0.168 [0.822, 1.481] 1.176 0.228 [0.730, 1.622]
b −1.406 0.193 [−1.784,−1.028] −1.217 0.236 [−1.680, 0.236]
c 0.821 0.124 [0.578, 1.063] 0.930 0.168 [0.600, 1.260]
d 0.723 0.166 [0.398, 1.049] 0.774 0.230 [0.323, 1.225]
Table 12: VUS estimates for CA125
estimated VUS sd 95% C.I.
Full 0.566 0.037 [0.495, 0.638]
BRL full 0.545 0.040 [0.467, 0.623]
BRL vb 0.511 0.048 [0.417, 0.605]
FI 0.515 0.040 [0.436, 0.594]
MSI 0.518 0.042 [0.437, 0.600]
IPW 0.550 0.042 [0.469, 0.631]
SPE 0.558 0.044 [0.471, 0.645]
with verification bias has the smallest value 0.511, and the empirical method applied to
the full dataset has the largest value 0.566. Also it seems that the BRL method applied
to the data with verification bias has the largest standard deviation.
To better compare the fitted ROC surface using all those methods, we also plot out
the ROC surface.
We can from Figure 1 that since the BRL method assumes trinormality while other
methods do not, BRL generates a smooth surface. Often a smooth surface is desirable as
it is more realistic. The ROC surface fitted using FI looks very similar to the one fitted
by the BRL method. The other three estimated surfaces using the data with verification
bias (i.e., MSI, IPW, SPE), look more like the empirical estimator.
For the ROC surface for CA153, the estimates with full data using BRL methods
applying on the full dataset and on the data with verification bias are mostly similar, having
difference within 0.2. Also the posterior standard deviation increases under verification
bias.
The estimates of VUS using all the methods are shown in Table 14. The estimates are
very similar, with FI giving the largest estimate while IPW giving the smallest.
The fitted ROC surface is shown in Figure 2, which gives a qualitatively similar result,
i.e., the ROC surface fitted using FI estimator is smoother and looks very much like surface
fitted by BRL. The other three estimated surface on data with verification bias (i.e., MSI,
IPW, SPE) look like the empirical full estimator.
No matter which estimation method we choose to use, the estimated VUS seems to
Table 13: Parameter estimates from BRL methods for CA153
full with verification bias
estimate sd 95% C.I. estimates sd 95% C.I.
a 1.356 0.153 [1.205, 1.508] 1.272 0.229 [0.823, 1.721]
b −0.407 0.169 [−0.574,−0.240] −0.407 0.220 [−0.838, 0.024]
c 0.907 0.140 [0.769, 1.046] 0.787 0.169 [0.456, 1.118]
d 0.816 0.164 [0.653, 0.978] 0.699 0.218 [0.272, 1.126]
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Figure 1: Estimated ROC surfaces for CA125
Table 14: VUS estimates for CA153
estimated VUS sd 95% C.I.
Full 0.356 0.037 [0.284, 0.427]
BRL full 0.363 0.033 [0.330, 0.396]
BRL vb 0.360 0.045 [0.314, 0.405]
FI 0.393 0.041 [0.313, 0.474]
MSI 0.385 0.042 [0.302, 0.468]
IPW 0.349 0.048 [0.256, 0.443]
SPE 0.360 0.053 [0.256, 0.464]
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Figure 2: Estimated ROC surfaces for CA153
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Table 15: Youden Index estimates for CA125
YI estimate sd 95% C.I.
Full 0.901 0.076 [0.751, 1.051]
BRL full 0.813 0.070 [0.675, 0.951]
BRL vb 0.753 0.081 [0.594, 0.912]
FI 0.792 0.073 [0.649, 0.935]
MSI 0.811 0.081 [0.653, 0.969]
IPW 0.899 0.100 [0.703, 1.095]
SPE 0.924 0.102 [0.724, 1.124]
Table 16: Youden Index estimates for CA153
YI estimate sd 95% C.I.
Full 0.592 0.078 [0.439, 0.745]
BRL full 0.513 0.055 [0.405, 0.621]
BRL vb 0.502 0.074 [0.356, 0.647]
FI 0.543 0.076 [0.394, 0.692]
MSI 0.619 0.088 [0.447, 0.791]
IPW 0.638 0.099 [0.445, 0.831]
SPE 0.676 0.101 [0.479, 0.873]
suggest the same result, namely, the 95% C.I. for CA125 is always above the 95% C.I. for
CA 153. That is, CA125 is more accurate in predicting cancer than CA153. A formal com-
parison would involve a hypothesis testing of two AUC values, which will not be discussed
further here.
Youden Index (YI) is another widely used measure of the accuracy of a classifier
(Youden, 1950). We estimate the Younden Index based on different the estimated ROC
surface. For BRL full and BRL vb method, the trinormality assumption gives an explicit
formula (Luo and Xiong, 2013). For other methods, numerical calculation will be used.
The posterior standard deviations of BRL full and BRL vb are calculated in Monte Carlo
simulation, while the standard deviations for others will be calculated using the bootstrap
method with 1000 resamples.
Estimates of the Youden Index given by different methods are slightly different from
each other, with IPW and SPE mostly giving higher estimates and higher standard devi-
ation, The BRL method applied to the full data or data under verification bias give lower
estimation result and smaller standard deviation. However, all of them consistently sug-
gesting that CA 125 is a better classifier for cancer, which coincides with the conclusion
we get from VUS estimation.
5 Appendix
Proof of Lemma 2.1 According to Bayes’ theorem, we have
P(Di = 0|Qi = t, Li = 3) = P(Di = 0)fQi(t|Di = 0)P(Li = 3|Qi = t,Di = 0)∑2
d=0{P(Di = d)fQi(t|Di = d)P(Li = 3|Qi = t,Di = d)}
.
(24)
Here P(Li = 3|Qi = t,Di = d) = 1 − g(t) under the MAR model as specified in (10)
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for d = 0, 1, 2, plugging in the above equation, we get
P(Di = 0|Qi = t, Li = 3) =
λ0φ(µ1,σ1)(t)(1− g(t))
λ0φ(µ1,σ1)(t)(1− g(t)) + λ1φ(t)(1− g(t)) + λ2φ(µ2,σ2)(t)(1− g(t))
=
λ0φ(µ1,σ1)(t)
λ0φ(µ1,σ1)(t) + λ1φ(t) + λ2φ(µ2,σ2)(t)
,
and
P(Li = 3) =
∫
P(Li = 3|Qi = t)fQi(t)dt =
∫
(1−g(t)){λ0φ(µ1,σ1)(t)+λ1φ(t)+λ2φ(µ2,σ2)(t)}dt.
Similarly, we can prove that
P(Di = 0|Qi = t, Li 6= 3) =
λ0φ(µ1,σ1)(t)
λ0φ(µ1,σ1)(t) + λ1φ(t) + λ2φ(µ2,σ2), (t)
and
P(Li 6= 3) =
∫
P(Li 6= 3|Qi = t)fQi(t)dt =
∫
g(t){λ0φ(µ1,σ1)(t)+λ1φ(t)+λ2φ(µ2,σ2)(t)}dt.
Proof of Lemma 2.2 According to Bayes’ theorem, we have
fQ(t|L 6= 3) = P(L = 0 or 1 or 2|Q = t)fQ(t)∫
P(L = 0 or 1 or 2|Q = s)fQ(s)ds
=
g(t){(1− λ1 − λ2)φ(µ1,σ1)(t) + λ1φ(t) + λ2φ(µ2,σ2)(t)}∫
g(s){(1− λ1 − λ2)φ(µ1,σ1)(s) + λ1φ(s) + λ2φ(µ2,σ2)(s)}ds
=
g(t)φ(µ1,σ1)(t)∫
g(s)φ(µ1,σ1)(s)ds
× (1− λ1 − λ2)
∫
g(s)φ(µ1,σ1)(s)ds∫
g(s){(1− λ1 − λ2)φ(µ1,σ1)(s) + λ1φ(s) + λ2φ(µ2,σ2)(s)}ds
+
g(t)φ(t)∫
g(s)φ(s)ds
× λ1
∫
g(s)φ(s)ds∫
g(s){(1− λ1 − λ2)φ(µ1,σ1)(s) + λ1φ(s) + λ2φ(µ2,σ2)(s)}ds
+
g(t)φ(µ2,σ2)(t)∫
g(s)φ(µ2,σ2)(s)ds
× λ2
∫
g(s)φ(µ2,σ2)(s)ds∫
g(s){(1− λ1 − λ2)φ(µ1,σ1)(s) + λ1φ(s) + λ2φ(µ2,σ2)(s)}ds
=(1− λ∗1(µ1,σ1,µ2,σ2,g) − λ∗2(µ1,σ1,µ2,σ2,g))φ∗(µ1,σ1,g)(t)
+ λ∗1(µ1,σ1,µ2,σ2,g)φ
∗
(g)(t) + λ
∗
2(µ1,σ1,µ2,σ2,g)
φ∗(µ2,σ2,g)(t),
where λ∗1(µ1,σ1,µ2,σ2,g), λ
∗
2(µ1,σ1,µ2,σ2,g)
and φ∗(µ,σ,g)(t) are defined in (16).
Proof of Theorem 2.3 Although verification model g and transformation H can be
unknown for our method, we can treat them as known for the proof of consistency of
the posterior distribution of (µ1, σ1, µ2, σ2) since given the labels and ranks, the posterior
distributions of (µ1, σ1, µ2, σ2) no longer depend on g and H.
Let the set of all permutations of {1, 2, ..., N} be denoted by ΩN . We want to show the
existence of a function h∗ : Ω1 ×Ω2 × ...× {0, 1, 2, 3}∞ → R− ×R+ ×R+ ×R+, such that
(µ1, σ1, µ2, σ2) = h
∗(RN , N ≥ 1, (L1, L2, ...)), then in view of Doob’s Theorem (Ghosal
and Van der Vaart(2017) Theorem 6.9 and Proposition 6.10), the proof Theorem 2.4 will
follow.
Let 1 ≤ i1 < ... < iN∗ ≤ N be the collection of subject’s indices whose label is verified,
i.e., Lij = 0, 1 or 2, and j = 1, ..., N∗. From Lemma 2.3,
fQ(t|L 6= 3) =(1− λ∗1(µ1,σ1,µ2,σ2,g) − λ∗2(µ1,σ1,µ2,σ2,g))φ∗(µ1,σ1,g)(t) + λ∗1(µ1,σ1,µ2,σ2,g)φ∗(t)
+ λ∗2(µ1,σ1,µ2,σ2,g)φ
∗
(µ2,σ2,g)
(t).
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So the overall verified samples can be regarded as being generated independently from this
mixture distribution disregarding the true disease status. So we have,
Qij
i.i.d.∼ (1− λ∗1(µ1,σ1,µ2,σ2,g) − λ∗2(µ1,σ1,µ2,σ2,g))Φ∗(µ1,σ1,g) + λ∗1(µ1,σ1,µ2,σ2,g)Φ∗(g)
+ λ∗2(µ1,σ1,µ2,σ2,g)Φ
∗
(µ2,σ2,g)
,
where Φ∗(µ1,σ1,g), Φ
∗
(g) and Φ
∗
(µ2,σ2,g)
are the cumulative distribution functions of φ∗(µ1,σ1,g),
φ∗(g) and φ
∗
(µ2,σ2,g)
, respectively. Thus we have
U∗j ={(1− λ∗1(µ1,σ1,µ2,σ2,g) − λ∗2(µ1,σ1,µ2,σ2,g))Φ∗(µ1,σ1,g)
+ λ∗1(µ1,σ1,µ2,σ2,g)Φ
∗
(g) + λ
∗
2(µ1,σ1,µ2,σ2,g)
Φ∗(µ2,σ2,g)}(Qij )
i.i.d.∼ Uniform(0, 1).
Let (R′N∗1, ..., R
′
N∗N∗) and (L
′
N∗1, ..., L
′
N∗N∗) be the rank vector and labels of (U
∗
1 , ..., U
∗
N∗)
respectively. According to Theorem a on page 157 of Hájek, J. and Šidák(1967), we have
E
(
U∗j −
R′N∗ij
N∗ + 1
)2
=
1
N∗
N∗∑
k=1
E
[(
U∗j −
k
N∗ + 1
)2|R′N∗ij = k]
=
1
N∗
N∗∑
k=1
k(N∗ − k + 1)
(N∗ + 1)2(N∗ + 2)
<
1
N∗
,
so E
(
U∗j −
R′N∗ij
N∗ + 1
)2
→ 0 as N →∞. Therefore, there exists a subsequence {N∗k} of {N∗}
such that for j ≥ 1, U∗j = limk→∞
R′N∗kij
N∗k + 1
, a.s.. Thus we can claim U∗j = hj(RN , N ≥
1, L1, L2, ...) for some function hj : Ω1 × Ω2 × ...× {0, 1, 2, 3}∞ → [0, 1].
Now given {Qij : Lij = 1} i.i.d.∼ Φ∗(g), so that {U∗j : Lij = 1}
i.i.d.∼ V(µ1,σ1,µ2,σ2,g), where
V(µ1,σ1,µ2,σ2,g) is the distribution of
{(1− λ∗1(µ1,σ1,µ2,σ2,g) − λ∗2(µ1,σ1,µ2,σ2,g))Φ∗(µ1,σ1,g) + λ∗1(µ1,σ1,µ2,σ2,g)Φ∗(g)
+λ∗2(µ1,σ1,µ2,σ2,g)Φ
∗
(µ2,σ2,g)
}(ξ),
with ξ ∼ Φ∗(g). Since (U∗j : Lij = 1) are i.i.d, V(µ1,σ1,µ2,σ2,g) is consistently estimable. So
we only need to show that the family of {V(µ1,σ1,µ2,σ2,g) : µ1 < 0, σ1 > 0, µ2 > 0, σ2 > 0} is
identifiable, i.e., if V(µ1,σ1,µ2,σ2,g) = V(µ′1,σ′1,µ′2,σ′2,g), then (µ1, σ1, µ2, σ2) = (µ
′
1, σ
′
1, µ
′
2, σ
′
2).
To prove that, first of all, we can show that Φ∗(µ,σ,g) and Φ
∗
(µ′,σ′,g) are linearly indepen-
dent of each other given that (µ, σ) 6= (µ′, σ′). Otherwise, there exists some c1, c2 ∈ R
such that c1Φ∗(µ,σ,g)(t) + c2Φ
∗
(µ′,σ′,g)(t) = 0 for all t, i.e., c1φ
∗
(µ,σ,g)(t) + c2φ
∗
(µ′,σ′,g)(t) = 0
for all t. This contradicts with the linear independence between Φ(µ,σ) and Φ(µ′,σ′). In
addition, because µ1 < 0 and µ2 > 0, so Φ∗(µ1,σ1,g) and Φ
∗
(µ2,σ2,g)
are identifiable from each
other. Thus we have λ∗1(µ1,σ1,µ2,σ2,g) = λ
∗
1(µ′1,σ
′
1,µ
′
2,σ
′
2,g)
, λ∗2(µ1,σ1,µ2,σ2,g) = λ
∗
2(µ′1,σ
′
1,µ
′
2,σ
′
2,g)
,
Φ∗(µ1,σ1,g) = Φ
∗
(µ′1,σ
′
1,g)
, Φ∗(µ2,σ2,g) = Φ
∗
(µ′2,σ
′
2,g)
, which then implies that (µ1, σ1, µ2, σ2) =
(µ′1, σ′1, µ′2, σ′2).
Thus we can conclude that for some function h of (U1, U2, ..., L1, L2, ...), and conse-
quently for a function h∗ of all ranks and labels,
(µ1, σ1, µ2, σ2, g) = h(U1, U2, ...)
= h(h1(RN , N ≥ 1, L1, L2, ...), h2(RN , N ≥ 1, L1, L2, ...), ...)
= h∗(RN , N ≥ 1, L1, L2, ...).
This justified the condition of Doob’s theorem and hence theorem holds at (µ∗1, σ1∗, µ∗2, σ∗2)a.e.[ν].
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